Introduction {#S6}
============

Obesity is a chronic metabolic disease characterized by an excessive accumulation of body fat. It is one of the most severe public health problems, associated with a series of disorders including diabetes, cancer, cardiovascular disease, osteoarthritis and obstructive sleep disease ^[@R1]^. Approximately 2.1 billion people globally are overweight or affected by obesity, and the prevalence has been increasing substantially ^[@R2]^. In the United States alone, the total economic cost related to obesity was more than \$215 billion annually as of 2010 ^[@R3]^. Obesity has been a global leading cause of morbidity and mortality that imposes an enormous burden on public health.

Though obesity can be attributable to lifestyle and cultural factors, such as lack of exercise and excessive calorie intake, the presence of an underlying genetic effect is indisputable ^[@R4]^. The heritability of obesity is up to 70% ^[@R5]^, which is significantly higher than that of many other complex traits such as hypertension (29%) ^[@R6]^. Family, twin, and adoption studies have also indicated a strong genetic determination of human obesity ^[@R7],\ [@R8]^. In developed countries, 60%--70% of the variation in obesity-related phenotypes appears to be heritable ^[@R9],\ [@R10]^.

Body mass index (BMI), defined as the body weight in kg divided by squared height in meters (kg/m^2^), is currently the standard measure of obesity due to its simplicity. To date, a variety of genome-wide association studies (GWASs) and meta-analyses have been conducted and hundreds of genetic variants have been identified for BMI ^[@R11],\ [@R12]^, accounting for 5% of total heritability.

Despite its popularity and simplicity, BMI is never the ideal phenotype to measure obesity. Human body mass is a complex composite of fat mass, lean mass, bone mass and other soft tissues. Among them, it is only fat mass that induces obesity and causes a series of adverse clinical manifestations ^[@R13]^. Therefore, fat mass is the only accurate and ideal phenotype to measure obesity. Nonetheless, research using fat mass as a measure for obesity is sparse, partly due to the difficulty of accurately measuring and collecting the phenotype.

Among various types of fat-induced obesity, abdominal obesity is perhaps the most severe. Fat stored in the abdomen is more harmful than fat stored at other body regions. For example, truncal adiposity confers a 3-fold increased risk for heart disease in women compared with accumulation of body fat in the gluteal femoral region ^[@R14]^. Moreover, fat mass stored more centrally leads people to be more susceptible to cardiovascular diseases and endocrine disorders ^[@R15]^. Truncal adiposity is also related to a reduction in endogenous growth hormone in women without generalized obesity ^[@R16]^, and with other health conditions, such as skeletal damage ^[@R17],\ [@R18]^, pain ^[@R19]^ and liver disease ^[@R20]^. The correlation between an accumulation of abdominal fat with an increased risk of metabolic disturbances is also found in children ^[@R21]^.

In the present study, we aim to uncover the genetic basis of abdominal obesity by conducting a genome-wide association meta-analysis of trunk fat mass in 11,569 subjects. We then perform a series of functional experiments and analyses to fine-map the causal variants and genes. We conduct eQTL analysis, *in vitro* dual-luciferase assay and EMSA assay to investigate the functional relevance of the identified variants. We also perform differential gene expression analysis in humans to examine the association of relevant gene expression with obesity susceptibility.

Methods {#S7}
=======

Ethics statement {#S8}
----------------

Samples used in this study are from multiple research and/or clinical centers. All samples were approved by the respective institutional ethics review boards, and all participants signed informed consent documents before being enrolled into the study.

Study populations {#S9}
-----------------

Six GWAS samples were incorporated in our study, of which three were from in-house studies and the other three were accessed through the NCBI Database of Genotypes and Phenotypes (dbGAP). The in-house samples include two of European population, with 1,000 and 2,286 unrelated individuals, and one of Chinese Han population with 1,627 unrelated individuals ^[@R22]^. The fourth sample was derived from the Framingham Heart Study (FHS), a longitudinal and prospective cohort comprising over 16,000 participants of European ancestry spanning three generations ^[@R23]^. A total of 6,004 phenotyped individuals were included. Both the fifth and sixth samples were derived from the Women's Health Initiative (WHI) observational study, a partial factorial randomized and longitudinal cohort with over 12,000 genotyped women, aged 50-79 years, of African-American or Hispanic ancestry ^[@R24]^. The fifth sample comprises 847 phenotyped individuals of African-American ancestry, and the sixth sample comprises 445 phenotyped individuals of Hispanic ancestry.

Phenotype measurements and modeling {#S10}
-----------------------------------

Trunk fat mass was measured by dual energy x-ray absorptiometry (DXA) machines (either Lunar Corp., Madison, WI, USA; or Hologic Inc, Bedford, MA, USA). In all the samples, covariates, including gender, age, age\^^2^, height, height\^^2^ and the first ten principal components derived from genome-wide genotype data were screened for significance with the stepwise linear regression model implemented in the stepAIC function of R package MASS. To correct for the effect of lean mass, trunk lean mass was taken as covariate as well. Regression residuals were transformed into a standard normal distribution by the inverse quantiles of standard normal distribution. Normalized residuals were used for subsequent association analysis.

Genotyping and quality control {#S11}
------------------------------

All GWAS samples were genotyped by high-throughput SNP genotyping arrays (Affymetrix Inc., Santa Clara, CA, USA; or Illumina Inc., San Diego, CA, USA within individual samples) according to the manufacturers' protocols. Quality control (QC) within each sample was implemented at both the individual level and SNP level. At the individual level, sex compatibility was checked by imputing sex from X-chromosome genotype data with Plink ^[@R25]^. Individuals of ambiguous imputed sex or with inconsistent imputed sex with the reported one were removed. At the SNP level, SNPs violating the Hardy-Weinberg equilibrium (HWE) rule (p-value\<1.0×10^−5^) were removed. In the familial sample FHS, genotypes having the Mendel error were set to missing.

Genotype imputation {#S12}
-------------------

GWAS samples were imputed to the 1000 Genomes Project phase 3 sequence variants (as of May 2013) ^[@R26]^. Genotype imputation reference panels of 503 individuals of European ancestry, 504 individuals of East Asian ancestry, 661 of African ancestry, and 347 of admixed American ancestry were downloaded from the project website. Each GWAS sample was imputed by respective reference panel with the closest ancestry. Haplotypes of bi-allelic variants, including SNPs and bi-allelic insertions/deletions (indels), were extracted to form reference panels for imputation. As a QC procedure, variants with zero or one copy of minor alleles were removed.

Prior to imputation, a consistency test of allele frequency between the GWAS sample and the reference sample was examined with the chi-square test. To correct for potential mis-strandedness, GWAS SNPs that failed the consistency test (p\<1.0×10^−6^) were transformed into the reverse strand. SNPs that again failed the consistency test were removed from the GWAS sample.

Imputation was performed with FISH, an algorithm that we developed to impute the diploid genome without the need to phase genotype into haplotype^[@R27]^. The method calculates an exact form of transition matrix in the segmental hidden Markov model, and is therefore accurate, fast and computer memory efficient. The software parameters were set by default.

Individual study association testing {#S13}
------------------------------------

Each GWAS sample was tested for association between normalized phenotype residual and genotyped and imputed genotypes under an additive mode of inheritance. For unrelated samples, association was examined by the linear regression model with MACH2QTL ^[@R28]^, in which allele dosage was taken as predictor for phenotype. For the FHS sample, a mixed linear model was used to account for genetic relatedness within each pedigree ^[@R29]^. Genomic control inflation ^[@R30]^ was estimated for each individual GWAS.

Meta-analysis {#S14}
-------------

Summary association signals from individual samples were combined for meta-analysis. Meta-analysis was performed by a weighted fixed-effects model with METAL ^[@R31]^, where weight was proportional to the inverse variance of regression coefficient. As a QC procedure, only common or less common (MAF≥0.01) and well imputed (imputation r^2^≥0.3 in at least two samples) SNPs were included for analysis. Between-study heterogeneity effect was measured by *I^2^* and Cochran's *Q* p-value ^[@R32]^. Genomic control inflation factor was estimated in meta-analysis.

Sensitivity analysis was performed by removing each study in turn and performing the same meta-analysis in the remaining samples.

*In silico* replication analysis {#S15}
--------------------------------

To verify the association signals of our identified SNP, we performed *in silico* replication analyses in three large-scale studies. The first was the GWAS scan of trunk fat mass in up to 331,093 UK-Biobank participants, in which trunk fat mass was measured by impedance approach. The analysis was performed by Dr. Neale's lab and the results were kindly released to be publicly available before publication. It should be noted that the phenotype being analyzed is trunk fat mass without adjusting for trunk lean mass. Summary association results were downloaded from the following link (<https://www.dropbox.com/s/zp05s9ucxjodf6b/23128.assoc.tsv.gz?dl=0>).

The second and third studies were two obesity-related traits analyzed by the Genetic Investigation of Anthropometric Traits (GIANT) consortium: BMI and waist-hip ratio adjusted for BMI (WHR~adj~) ^[@R33],\ [@R34]^. Cross-validation in these two related traits strengthens the confidence towards true association in the present study. Summary association results were downloaded from the GIANT consortium website (<http://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_file>).

Cis-expression quantitative trait loci (cis-eQTL) analysis {#S16}
----------------------------------------------------------

To investigate the association between the identified SNP polymorphisms and the nearby gene expressions, we performed cis-eQTL analysis. The datasets we used were derived from the GTEx project ^[@R35]^. The GTEx project collected RNA-sequenced multiple human tissues (up to 11,614) from donors who were also densely genotyped, and analyzed for associations between SNPs and global RNA expression within individual tissues. Three obesity-related tissues, including subcutaneous adipose (N=385), visceral adipose (N=313) and whole blood (N=369), were analyzed. Single tissue eQTL association results were downloaded from the GTEx website (<http://www.gtexportal.org/home/>).

Dual-luciferase reporter assay {#S17}
------------------------------

We conducted a dual-luciferase reporter assay to determine whether the regulation of *PTBP2* expression by *rs12409479* was through regulating its promoter activity. Human embryonic kidney cell line 293T (HEK293T cells) were cultured in DEME high glucose (Hyclone, Thermo Fisher Scientific Inc.) supplemented with 10% fetal bovine serum (FBS, Tianhang Inc.), 100 U mL^−1^ penicillin, and 100μg mL^−1^ streptomycin. Cells were maintained at 37°C in a water-saturated atmosphere under 5% CO~2~ in air, and were cultured to 60%−80% in 12-well or 24-well culture plate before transfection.

Luciferase reporter plasmid containing *PTBP2* promoter was constructed by inserting a 2095 bp sequence containing *PTBP2* promoter (ENST00000370197.5; *PTBP2*-201) into the *KpnI* and *HindIII* sites of the pGL3-basic vector (Promega Corporation, Madison, WI, USA), which expresses the *Firefly* luciferase gene. This pGL3-PTBP2-Promoter construct served as a negative control. For the experimental group, a 225 bp DNA sequence centered at *rs12409479* (chr1:968,006,63-968,008,87) was cloned into the 5′-end of the above pGL3-PTBP2-Promoter vector, forming the pGL3-rs12409479-PTBP2-Promoter construct. We cloned two types of sequence, each containing either allele A or allele G of *rs12409479*. The success of plasmid construction was confirmed by DNA Sanger sequencing. The construct was then transfected into the 293T cells using the jetPRIME transfection reagent (PolyPlus-transfection, France). As an internal control for transfection efficiency, the pRL-TK vector (Promega Corporation, Madison, WI, USA) expressing the *Renilla* luciferase gene was co-transfected at the same time. The cells were collected for luciferase activity measurement after 24h of transfection. We conducted 8 replicates under each experimental condition, and 4 replicates under the null condition.

Luciferase activity was measured using the dual-luciferase reporter system (Promega Corporation, Madison, WI, USA) following the manufacturer's instructions. The ratio of *Firefly* to *Renilla* luciferase activity was compared between the pGL3-rs12409479-PTBP2-Promoter construct and the pGL3-PTBP2-Promoter control construct. We also compared the control construct with the null pGL3-basic vector containing no *PTBP2* promoter to examine the transcription efficacy of the promoter, and compared between two allelic experiment groups. Statistical significance was tested using an unpaired Student's t-test.

Electrophoretic mobility shift assay (EMSA) {#S18}
-------------------------------------------

We further conducted EMSA to explore whether the oligonucleotide sequence containing the identified SNP binds to transcription factors, and whether the binding activity is allelic specific. Oligonucleotides including biotin-labeled probes and competitor probes were synthetized by Sangon Biotech (Shanghai, China), with HPLC purifying approach. 5×binding buffer was purchased from Beyotime Biotech (Shanghai, China). Total protein was extracted from the 293T cells and stored in aliquots at −80°C until use.

For each sequence containing either a major or minor allele, the following three conditions were conducted in a total volume of 10μl: 1) Negative control: 1μl of biotin-labeled probe (0.07 μM) was incubated with 2ul of 5×binding buffer containing poly (dI-dC), a non-specific competitor of DNA. The mixture was incubated at 25°C for 20 min. 2) Binding reaction: Before adding biotin-labeled probes for 20min at room temperature, 5×binding buffer was pre-incubated with total protein at 25°C for 10 min. 3) Competition reaction: 100-fold excess of unlabeled probe was added to the reaction mixture (5×binding buffer and total protein) for 20min prior to the addition of the labeled probe. The binding reaction products were then separated via electrophoresis at 80V for 2 hours on 6% nondenaturing polyacrylamide gel with 0.5×Tris-borate-EDTA running buffer. Finally, the DNA-protein complexes were detected using the Chemiluminescent EMSA kit (Beyotime, China) according to the manufacturer's instructions.

Differential gene expression analysis {#S19}
-------------------------------------

To establish a relationship between the relevant genes and obesity development, we examined differential gene expression levels in datasets accessed through the Gene Expression Omnibus (GEO) repository ([www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo/)).

We restricted the datasets to fat or adipose tissue-related human subjects/tissues. After searching the GEO web portal using the terms "adipose tissue," "adiposity," and "adipose stem cell," we identified 30 datasets. After careful examination of the retrieved items, 7 datasets were available for analysis, as described in a previous study ^[@R36]^. In each dataset, we grouped subjects into case (obesity) group and control (non-obesity) group. Genome-wide gene expressions were logarithm-transformed and normalized. Normalized expression levels were compared between the two groups using the GEO online tool GEO2R ([ncbi.nlm.nih.gov/geo/geo2r/](http://ncbi.nlm.nih.gov/geo/geo2r/)). The expression difference was characterized by logarithm transformed fold change (logFC) and p-value.

Results {#S20}
=======

Meta-analysis {#S21}
-------------

Basic characteristics of the GWAS meta-analysis samples are listed in [Supplemental Table 1](#SD1){ref-type="supplementary-material"}. Principal component analysis (PCA) was applied to each individual sample, and no population outlier was observed. A total of 28,855,047 bi-allelic variants were imputed into the 1000 Genomes Project reference panel. After filtering out rare variants and variants of poor imputation certainty, 12,061,510 variants were retained for association analysis. After adjusting the phenotype by PCA in each individual study, the genomic control inflation factor was small (λ=1.04), indicating the limited effect of population stratification. A logarithmic quantile-quantile (QQ) plot of meta-analysis test statistics shows a marked deviation in the tail of the distribution, suggesting the possible existence of a true association ([Supplemental Figure 1](#SD3){ref-type="supplementary-material"}).

A total of 3 SNPs at 3 genomic loci were identified at the genome-wide significance level (GWS, 5.0×10^−8^): 1p21 (*rs12409479*, p=7.26×10^−10^), 8q21.3 (*rs2091921*, p=3.21×10^−10^), and 20p11 (*rs4813371*, p=1.71×10^−8^). At a less stringent significance level 1.0×10^−7^, 5 additional SNPs were identified. Of those, 4 are located in the same locus 20p11 as *rs4813371*, and are in strong LD with the latter. The fifth SNP *rs6011111* (p=9.85×10^−8^) presented a significant heterogeneity effect (I^2^=56.8%, Q p=0.04). Manhattan plot of the GWAS meta-analysis is shown in [Figure 1](#F1){ref-type="fig"}.

Among the 3 identified loci, 20p11 was previously reported for body fat mass (BFM), with the lead SNP being *rs2069126* ^[@R36]^. *rs2069126* is associated with TFM~adj~ in the present study as well (p=1.21×10^−6^), though the signal does not reach the GWS level. *rs2069126* and *rs4813371* are 10.0 kb apart, and the two SNPs have modest LD (r^2^=0.33), implying that their signals arise from same association source.

Both *rs2091921* and *rs12409479* at the remaining two identified loci are polymorphic in the three samples (OOS, KCOS and FHS) of European population and in the WHI-HIS Hispanic population sample, but are monomorphic in the samples of Chinese population (COS) and of African population (WHI-AFR). Sensitivity analysis shows that the association at *rs2091921* is entirely driven by the KCOS sample (p=5.49×10^−10^), but is not significant in any of the other samples. Meta-analysis of the remaining samples excluding the KCOS sample reveals that the association becomes non-significant (p=0.12). At *rs12409479*, the association is mainly driven by the KCOS sample as well (p=6.22×10^−8^), but is also significant in the larger FHS sample (p=0.01). For meta-analysis of the remaining samples excluding the KCOS sample, the association remains significant (p=2.12×10^−3^). Given the above sensitivity analysis results, we disregarded *rs2091921* and focused on *rs12409479* at 1p21 only.

*rs12409479* is a common SNP (MAF=0.07) in the European population. Allele A at this SNP tends to increase normalized trunk fat mass by 0.14 standard deviations per copy. It is located 386 kb 5′-upstream of *PTBP2* gene. The forest plot is displayed in [Figure 2](#F2){ref-type="fig"}, and the regional plot drawn by LocusZoom ^[@R37]^ is shown in [Supplemental Figure 2](#SD4){ref-type="supplementary-material"}.

The locus 1p21 encompassing *rs12409479* was previously identified for BMI and weight, tagged by multiple SNPs ^[@R12],\ [@R34],\ [@R38]--[@R40]^. The LD patterns between *rs12409479* and these SNPs are plotted in [Figure 3](#F3){ref-type="fig"}, and the association signals of these SNPs in the present study are listed in [Supplemental Table 2](#SD2){ref-type="supplementary-material"}. It is clear that *rs12409479* is independent of any of the other reported SNPs (r^2^=0.00-0.03), implying that it represents an independent signal.

*In silico* replication analysis {#S22}
--------------------------------

We tested whether *rs12409479* was significant in previous large GWAS meta-analyses of obesity-related traits. The first trait is trunk fat mass, analyzed in the UK-Biobank participants (N=331,093). The effect direction is consistent and the p-value is significant (one-sided p=3.39×10^−3^) in the UK-Biobank analysis, increasing the likelihood of a true association signal. We then surveyed the summary results released by the GIANT consortium for BMI and WHR~adj~ ^[@R33],\ [@R34]^. The effect directions in both traits are consistent, in that allele A corresponds to higher BMI and WHR~adj~ levels. For BMI, a weak association is observed in the sub-group of men of 50 years or older (N=93,201, p=0.06). The association is also weak for WHR~adj~, (N=110,204, p=0.07). Considering the one-sided nature of the replication effort, they are indeed nominally significant (one-sided p=0.03 and 0.04). The main results are listed in [Table 1](#T1){ref-type="table"}.

Cis-eQTL analysis {#S23}
-----------------

We performed cis-eQTL analysis in subcutaneous adipose tissue, visceral adipose tissue and whole blood of the GTEx project datasets. The results show that *rs12409479* polymorphisms are significantly associated with *PTBP2* gene expression in subcutaneous adipose tissue. Specifically, allele A is associated with a higher level of gene expression (p=4.15×10^−3^, N=385). The association is nonetheless not observed in either visceral adipose tissue (p=0.17, N=313) or whole blood (p=0.56, N=369), implying that the regulation pattern is specific to the subcutaneous adipose tissue.

Dual-luciferase reporter assay {#S24}
------------------------------

To determine whether the region encompassing *rs12409479* regulates *PTBP2* promoter activity, we conducted dual-luciferase reporter assay in HEK293T cells. Specifically, a 225 bp *rs12409479*-centered DNA fragment was cloned into the luciferase reporter vector containing *PTBP2* promoter. These constructs were transfected into HEK293T cells along with pRL-TK vector.

The luciferase reporter assay results are displayed in [Figure 4A](#F4){ref-type="fig"}. Compared to the null pGL3-basic vector, the control vector containing the *PTBP2* promoter significantly increases luciferase activity by over 30 fold (p=3.65×10^−7^), proving the successful construction of the *PTBP2* promoter in promoting luciferase gene expression. Compared to the pGL3-PTBP2-Promoter vector, the pGL3-rs12409479-PTBP2-Promoter vector containing either allele A or allele G significantly reduces *PTBP2* expression (p=8.52×10^−10^ or 1.82×10^−11^), with the reduction magnitude being up to 50%. This significant reduction suggests that the sequence containing *rs12409479* downregulates *PTBP2* gene expression by repressing *PTBP2* promoter activity. Between the two allele constructs, the expression of allele A is significantly higher than that of allele G (p=4.15×10^−3^), implying that the regulation is allelic specific.

EMSA {#S25}
----

We next performed EMSA to explore the possibility that *rs12409479* binds to unknown transcription factors in an allelic specific manner. The binding reactions were performed with labeled and competitor probes containing allele A or allele G of *rs12409479*. The labeled probe sequences are as follows:

forward primer

5′-biotin-TATAAATGGTGGGAAAAAGAAGAATATTTTCT**\[A/G\]**GCACATTAAAACTATATGAAGTTCAAATTTCA-3′;

reverse primer

5′-biotin-TGAAATTTGAACTTCATATAGTTTTAATGTGC**\[T/C\]**AGAAAATATTCTTCTTTTTCCCACCATTTATA-3′.

The EMSA results are shown in [Figure 4B](#F4){ref-type="fig"}. The shifted bands at the same migration position are observed in labeled probes for both allele A (lane 2) and allele G (lane 5) when compared to negative controls (lane 1 and lane 4), demonstrating their binding affinity to the same transcription factor. The two shifted bands are completely eliminated by the addition of 100-fold excess unlabeled A-allele probe (lane 3) and G-allele probe (lane 6), indicating that the binding is specific to the sequence motif containing *rs12409479*. Between the two alleles, the signal intensity for allele A (lane 2) is stronger than that for allele G (lane 5), suggesting that the former is more capable of binding to the transcription factor than the latter. Collectively, the EMSA results reveal differential binding activities of the two alleles to the same transcription factor.

Differential gene expression analysis (DGEA) {#S26}
--------------------------------------------

To provide biological insight into the role of *PTBP2* in fat development, we explored its differential expression in datasets accessed through the GEO repository. Of the seven datasets accessed through the GEO repository, the expression of *PTBP2* is significantly different in two datasets (GSE29718, N=20, p=0.04; GSE9624, N=11, p=9.22×10^−3^). The effect directions in both datasets are consistent in that obese subjects tend to have increased gene expression compared to non-obese subjects.

Discussion {#S27}
==========

In the present study, we have performed a genome-wide association meta-analysis of TFM~adj~ in 11,569 participants from 6 GWAS samples, and have identified a functional variant *rs12409479* at 1p21, which is independent of any previously reported variants for obesity-related traits. Moreover, through a series of functional investigations, we have hypothesized a regulating path from *rs12409479* to trunk fat mass development through its regulation of *PTBP2* gene expression.

Abdominal fat is located in two major compartments: subcutis and viscera. Truncal subcutaneous fat may exert a greater effect on risk factors than visceral fat does because of its larger mass ^[@R41]--[@R43]^. Combining the genetic association analyses with the bioinformatical and functional investigations, we have hypothesized a regulating path from *rs12409479* to fat mass development through its allele specific regulation of *PTBP2* gene expression, as displayed in [Figure 5](#F5){ref-type="fig"}. GWAS, dual luciferase, EMSA and cis-eQTL experiments consistently supported the upregulated role of allele A in regulating *PTBP2* expression, which in turn upregulated the accumulation of trunk fat mass.

In this study, we used fat mass instead of BMI as the phenotype to measure obesity. BMI is calculated with total body mass, which is composed of not only fat mass but also lean mass, bone and other soft tissues. Therefore, BMI is unable to discriminate fat mass from other compartments. On the other hand, the majority of human body weight comes from lean mass, while obesity is mainly induced by the excessive storage of fat mass. Unlike fat mass, lean mass has a positive effect on physical fitness, higher caloric expenditure and exercise capacity ^[@R44]^. Therefore, using BMI to classify obesity may provide misleading information about body fat content and risk assessment.

*PTBP2* encodes an RNA binding protein that is involved in several post-transcriptional regulatory events of gene expression, including exon splicing. High levels of *PTBP2* expression are observed in adult brain and muscles, suggesting its role in the physiology of cardiometabolic phenotypes ^[@R45]^. It is notable that the central nervous system (CNS) plays an important role in obesity etiology. In addition, overexpression of the *PTBP2* protein exhibited multiple functions related to the stability and splicing profile of the *Nova1* gene, which abolishes brown adipogenesis ^[@R46]^. Several variants previously established for obesity-associated traits, such as BMI, weight and waist circumference, are close to *PTBP2* ^[@R12],\ [@R34],\ [@R38]--[@R40],\ [@R47]^, implying that it might play an important role in human fat storage and obesity development.

Regulatory variants in noncoding regions are thought to explain much more heritability than coding regions for certain diseases ^[@R48]^. Most regulatory elements are located in introns and intergenic regions ^[@R49]^. In addition, recent studies have demonstrated that regulatory risk variants could bind to transcription factors and induce allele-specific effects on the expression of distal gene by long-range interactions ^[@R49]--[@R51]^. In this study, the identified SNP *rs12409479* is located 386 kb upstream from the *PTBP2* gene. Its allele-specific effects on *PTBP2* gene expression have been verified by eQTL analysis and functional experiments. Dual-luciferase reporter assay results imply that the region acts as a repressor to *PTBP2* expression. Extensive functional investigations are warranted to verify the biological mechanism.

Though \~12 million variants were analyzed, the genome-wide significance level was set at 5.0×10^−8^. This is because most of the common variants are locally abundant due to the linkage disequilibrium pattern. It has been estimated that the effective number of independent common variants is approximately one million throughout the genome, resulting in a genome-wide significance level of 5.0×10^−8\ [@R52]^. Even at a more stringent significance level, the identified novel SNP *rs12409479* remains significant at the discovery stage (p=7.26×10^−10^).

Certain limitations exist in the present study. First, the discovery samples are from diverse populations, which may complicate the interpretation of the results in the presence of population specificity for associated loci. However, the identified SNP *rs12409479* is polymorphic only in European and Hispanic populations, and is monomorphic in East Asian and African populations. The relatively limited sample size of Hispanic population (WHI-HIS N=445, 5%) has a minor effect on the association results. Therefore, we do not expect that trans-ancestral samples would pose a problem for the interpretation of our results, particularly at *rs12409479*. Second, the EMSA assay could only qualitatively visualize the binding affinity to an unknown transcription factor, but could not identify the specific transcription factor. Experiments with finer resolution, such as DNA pull-down assay followed by protein mass spectrum or super-sift assay with a hypothesized protein antibody, may identify the specific transcription factor, which is out of the scope of the present study.

In conclusion, by performing a genome-wide association meta-analysis of TFM~adj~ in 11,569 subjects from 6 GWAS samples, we have identified an independent functional variant *rs12409479* at 1p21, and have hypothesized a regulating path from *rs12409479* to trunk fat mass development through its allelic specific regulation of *PTBP2* gene expression. Our findings may provide useful insights that further improve our understanding of abdominal obesity.
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![Manhattan plot of the meta-analysis.\
The results from the meta-analysis are plotted against the position on each of the 22 chromosomes. The black dashed line indicates the threshold for genome wide significance level (α=5.0×10^−8^).](nihms-1519943-f0001){#F1}

![Forest plot of *rs12409479* meta-analysis.\
Regression coefficient (beta) and its 95% confidence interval (CI) are presented in un-transformed estimates from individual studies. "Total" refers to the combined meta-analysis.](nihms-1519943-f0002){#F2}

![Linkage disequilibrium pattern between *rs12409479* and previously identified SNPs.\
A total of 7 SNPs were reported by previously GWAS meta-analyses of BMI and body weight (*rs10783050, rs11165643, rs10747472, rs3002271, rs587242, rs1555543, rs1973993*). Linkage disequilibrium (LD) pattern between each pair of these SNPs including *rs12409479* and the LD r^2^ value are displayed with Haploview ^[@R53]^. Five SNPs are clustered into a single haplotype block spanning 150 kb. *rs12409479* is in very low LD (r^2^=0.00-0.03) with any of the other SNPs, indicating that it is independent of all previous SNPs.](nihms-1519943-f0003){#F3}

![Dual-luciferase reporter assay and EMSA results.\
**(A) Dual-luciferase reporter assay result**. The pGL3-PTBP2-Promoter vector was set as a control. Sequence construct containing either allele A or allele G was inserted upstream of the gene promoter. Eight replicates were conducted under each of the three conditions. Compared to the null pGL3-basic vector, the vector containing the *PTBP2* promoter increases luciferase expression (p=3.65×10^−7^). Both allele A construct and allele G construct significantly reduce luciferase activity (both p\<0.01), suggesting that the sequence containing *rs12409479* represses *PTBP2* promoter activity. Between the two allele constructs, the expression of allele A is significantly higher than that of allele G (p=4.15×10^−3^), implying that the regulation is allelic specific. (**B**) **EMSA result.** EMSA was conducted using a biotin labeled A-allele probe or G-allele probe with total protein extracted from HEK293T cells, with or without unlabeled A-allele probe or G-allele probe competitor. The shifted bands at the same migration position are observed in labeled probes for both allele A (lane 2) and allele G (lane 5) when compared to the controls (lane 1 and lane 4), implying their binding affinity to the same transcription factor. The two shifted bands are completely eliminated by the addition of 100-fold excess unlabeled A-allele probe (lane 3) and G-allele probe (lane 6), demonstrating that the binding is specific to the sequence motif containing *rs12409479*. Between the two alleles, the signal intensity for allele A (lane 2) is stronger than that for allele G (lane 5, too weak to be observed without zooming in the figure), suggesting that the former is more capable of binding to transcription factor than the latter. \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001.](nihms-1519943-f0004){#F4}

![Hypothesized regulating path from *rs12409479* to trunk fat development.\
Based on our GWAS and functional investigation results, we hypothesized a regulating path from *rs12409479* to trunk fat through *PTBP2* gene. In this diagram, *rs12409479* binds to an unknown transcription factor to form a complex that regulates *PTBP2* gene expression. Specifically, allele A is more capable of binding to the transcription factor (EMSA) and upregulates *PTBP2* (eQTL). *PTBP2* in turn regulates trunk fat development in an upward direction (differential gene expression analysis). Consequently, allele A of *rs12409479* upregulates trunk fat mass, as evidenced by the association study. The red lines represent upregulation and the green lines represent downregulation.](nihms-1519943-f0005){#F5}

###### 

Main association results of *rs12409479* in studied samples

         Trait          Sample    Beta       SE              *P*            *N*     I^2^(%)
  -------------------- --------- ------ ------------- ------------------ --------- ---------
   GWAS meta-analysis                                                              
        TFM~adj~          OOS     0.12      0.11             0.3            888       \-
                         KCOS     0.16      0.03       **6.22×10^−8^**     1844       \-
                          FHS     0.11      0.04           **0.01**        6004       \-
                        WHI-HIS   0.11      0.08             0.13           445       \-
                         Meta     0.14      0.02       **7.26×10^−10^**    9181       0.0
                                                                                   
   Cross-replication                                                               
          TFM             UKB     0.01   5.12×10^−3^   **3.39×10^−3^**    331,093     \-
          BMI            GIANT    0.03      0.02           **0.03**       61,506      \-
        WHR~adj~         GIANT    0.02      0.01           **0.04**       110,204     \-

Notes: Beta is the regression coefficient of normalized phenotypic residual on the effect allele A. OOS, Omaha osteoporosis study; KCOS, Kansas City osteoporosis study; FHS, Framingham Heart Study; WHI-HIS was the Women's Health Initiative (WHI) cohort Hispanic subsample. TFM, trunk fat mass; TFM~adj~, trunk fat mass adjusted by trunk lean mass; BMI, body mass index; WHR~adj~, waist-hip ratio adjusted by BMI; UKB, UK-Biobank. Nominally significant *P* values are marked in bold.
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